These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15212065)

  • 1. Palivizumab and congenital heart disease.
    Kneyber MC
    J Pediatr; 2004 Jun; 144(6):837. PubMed ID: 15212065
    [No Abstract]   [Full Text] [Related]  

  • 2. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
    Chantepie A;
    Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 8. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Tulloh R; Marsh M; Blackburn M; Casey F; Lenney W; Weller P; Keeton BR;
    Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of palivizumab not justified.
    Clifford RD
    Thorax; 2006 Jun; 61(6):545-6; author reply 546. PubMed ID: 16738045
    [No Abstract]   [Full Text] [Related]  

  • 12. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence over a period of 8 years of patterns of prescribing palivizumab for patients with and without congenitally malformed hearts, and in admissions to paediatric intensive care.
    Turner A; Begg C; Smith B; Coutts J
    Cardiol Young; 2009 Aug; 19(4):346-51. PubMed ID: 19476692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
    Manzoni P; Leonessa M; Farina D; Gomirato G
    Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
    [No Abstract]   [Full Text] [Related]  

  • 15. A health care management company's experience with palivizumab--1 year later.
    Silverman W
    Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748
    [No Abstract]   [Full Text] [Related]  

  • 16. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
    Nakazawa M; Saji T; Ichida F; Oyama K; Harada K; Kusuda S
    Pediatr Int; 2006 Apr; 48(2):190-3. PubMed ID: 16635185
    [No Abstract]   [Full Text] [Related]  

  • 18. Synagis now registered for the prevention of RSV disease in children with CHD.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001434
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention in respiratory syncytial virus infections.
    Wolfs TF; Kimpen JL
    Pediatr Pulmonol; 2001; Suppl 23():86-7. PubMed ID: 11886161
    [No Abstract]   [Full Text] [Related]  

  • 20. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.